Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Barnard

Showing results (101-110 of 163) with videos related to

Pageof 17
Sort By:
Circulation. Genomic and Precision Medicine|March 17, 2018
Genetic Control of Left Atrial Gene Expression Yields Insights into the Genetic Susceptibility for Atrial FibrillationJeffrey Hsu, Shamone Gore-Panter, Gregory Tchou, et al.
Circulation. Arrhythmia and Electrophysiology|June 21, 2019
Machine Learning Prediction of Response to Cardiac Resynchronization Therapy: Improvement Versus Current GuidelinesAlbert K Feeny, John Rickard, Divyang Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2020
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 AbnormalitiesDavid A Sallman, John Barnard, Najla H Al Ali, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Iscience|March 17, 2023
A multimodal analysis of genomic and RNA splicing features in myeloid malignanciesArda Durmaz, Carmelo Gurnari, Courtney E Hershberger, et al.
Med (New York, N.Y.)|May 26, 2021
Increased Incidence of Venous Thromboembolism with Cancer ImmunotherapyJoanna Roopkumar, Shadi Swaidani, Ann S Kim, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
ERBB4 deficiency promotes atrial myopathy underlying the atrial fibrillation substrateNaoko Yamaguchi, John Santucci, Seok Jae Hong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimizationWilliam J Watkins, Lee Chong, Aesop Cho, et al.
Ebiomedicine|May 26, 2022
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5qVera Adema, Laura Palomo, Wencke Walter, et al.
Pageof 17

Showing results (101-110 of 163) with videos related to

Sort By:
Pageof 17
Circulation. Genomic and Precision Medicine|March 17, 2018
Genetic Control of Left Atrial Gene Expression Yields Insights into the Genetic Susceptibility for Atrial FibrillationJeffrey Hsu, Shamone Gore-Panter, Gregory Tchou, et al.
Circulation. Arrhythmia and Electrophysiology|June 21, 2019
Machine Learning Prediction of Response to Cardiac Resynchronization Therapy: Improvement Versus Current GuidelinesAlbert K Feeny, John Rickard, Divyang Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2020
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 AbnormalitiesDavid A Sallman, John Barnard, Najla H Al Ali, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Iscience|March 17, 2023
A multimodal analysis of genomic and RNA splicing features in myeloid malignanciesArda Durmaz, Carmelo Gurnari, Courtney E Hershberger, et al.
Med (New York, N.Y.)|May 26, 2021
Increased Incidence of Venous Thromboembolism with Cancer ImmunotherapyJoanna Roopkumar, Shadi Swaidani, Ann S Kim, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
ERBB4 deficiency promotes atrial myopathy underlying the atrial fibrillation substrateNaoko Yamaguchi, John Santucci, Seok Jae Hong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimizationWilliam J Watkins, Lee Chong, Aesop Cho, et al.
Ebiomedicine|May 26, 2022
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5qVera Adema, Laura Palomo, Wencke Walter, et al.
Pageof 17